このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Fusen Pharmaceutical 将来の成長

Future 基準チェック /06

現在、 Fusen Pharmaceuticalの成長と収益を予測するのに十分なアナリストの調査がありません。

主要情報

n/a

収益成長率

n/a

EPS成長率

Pharmaceuticals 収益成長	10.7%
収益成長率	n/a
将来の株主資本利益率	n/a
アナリストカバレッジ	None
最終更新日	n/a

今後の成長に関する最新情報

Recent updates

Fusen Pharmaceutical (HKG:1652) Use Of Debt Could Be Considered Risky

May 21

Fusen Pharmaceutical Company Limited's (HKG:1652) Popularity With Investors Under Threat As Stock Sinks 27%

Mar 31

We Wouldn't Rely On Fusen Pharmaceutical's (HKG:1652) Statutory Earnings As A Guide

Feb 08

Is Fusen Pharmaceutical Company Limited's (HKG:1652) Recent Price Movement Underpinned By Its Weak Fundamentals?

Jan 18

Does Fusen Pharmaceutical (HKG:1652) Have A Healthy Balance Sheet?

Dec 28

What You Need To Know About Fusen Pharmaceutical Company Limited's (HKG:1652) Investor Composition

Dec 07

If You Had Bought Fusen Pharmaceutical (HKG:1652) Shares A Year Ago You'd Have Earned 34% Returns

Nov 20

このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Fusen Pharmaceutical は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。

シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。

業績と収益の成長予測

SEHK:1652 - アナリストの将来予測と過去の財務データ ( )CNY Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2023	566	-36	-162	-73	N/A
9/30/2023	614	-24	-49	19	N/A
6/30/2023	663	-11	64	110	N/A
3/31/2023	577	-23	75	110	N/A
12/31/2022	492	-35	87	110	N/A
9/30/2022	414	-34	-5	38	N/A
6/30/2022	337	-34	-96	-34	N/A
3/31/2022	361	-9	-79	7	N/A
12/31/2021	386	17	-62	48	N/A
9/30/2021	420	48	-30	66	N/A
6/30/2021	454	79	3	83	N/A
3/31/2021	470	75	49	118	N/A
12/31/2020	487	70	95	153	N/A
9/30/2020	473	67	74	154	N/A
6/30/2020	458	65	53	154	N/A
3/31/2020	433	59	8	87	N/A
12/31/2019	407	53	-37	20	N/A
9/30/2019	397	63	-54	23	N/A
6/30/2019	387	72	-71	26	N/A
3/31/2019	424	87	-56	44	N/A
12/31/2018	462	102	-42	63	N/A
9/30/2018	507	102	37	95	N/A
6/30/2018	493	98	68	82	N/A
3/31/2018	473	98	96	107	N/A
12/31/2017	453	97	124	133	N/A
9/30/2017	427	86	N/A	91	N/A
12/31/2016	442	95	N/A	172	N/A
12/31/2015	369	45	N/A	70	N/A

アナリストによる今後の成長予測

収入対貯蓄率: 1652の予測収益成長が貯蓄率 ( 2.2% ) を上回っているかどうかを判断するにはデータが不十分です。

収益対市場: 1652の収益がHong Kong市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です

高成長収益: 1652の収益が今後 3 年間で大幅に増加すると予想されるかどうかを判断するにはデータが不十分です。

収益対市場: 1652の収益がHong Kong市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。

高い収益成長: 1652の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: 1652の自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Fusen Pharmaceutical 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Fusen Pharmaceutical Company Limited Provides Group Earnings Guidance for the Six Months Ended 30 June 2023

Fusen Pharmaceutical Company Limited Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2022

Recent updates

New minor risk - Market cap size

Fusen Pharmaceutical (HKG:1652) Use Of Debt Could Be Considered Risky

Fusen Pharmaceutical Company Limited, Annual General Meeting, May 28, 2024

CEO & Executive Director recently bought HK$224k worth of stock

Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Company Limited Announces National Medical Products Administration of the People's Republic of China Accepts the Application for Launching Metformin Empagliflozin Tablets (I)

Fusen Pharmaceutical Company Limited's (HKG:1652) Popularity With Investors Under Threat As Stock Sinks 27%

Full year 2023 earnings released: CN¥0.05 loss per share (vs CN¥0.046 loss in FY 2022)

Fusen Pharmaceutical Company Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

First half 2023 earnings released: EPS: CN¥0.022 (vs CN¥0.009 loss in 1H 2022)

First half 2023 earnings released: EPS: CN¥0.022 (vs CN¥0.009 loss in 1H 2022)

Fusen Pharmaceutical Company Limited to Report Q2, 2023 Results on Aug 29, 2023

Fusen Pharmaceutical Company Limited Provides Group Earnings Guidance for the Six Months Ended 30 June 2023

Executive Chairman recently bought HK$84k worth of stock

CEO & Executive Director recently bought HK$1.0m worth of stock

Full year 2022 earnings released: CN¥0.046 loss per share (vs CN¥0.022 profit in FY 2021)

Executive Chairman recently bought HK$1.1m worth of stock

Executive Chairman recently bought HK$918k worth of stock

CEO & Executive Director recently bought HK$375k worth of stock

Executive Chairman recently bought HK$791k worth of stock

Fusen Pharmaceutical (HKG:1652) Use Of Debt Could Be Considered Risky

Executive Chairman recently bought HK$2.3m worth of stock

Less than half of directors are independent

CEO & Executive Director recently bought HK$2.2m worth of stock

Executive Chairman recently bought HK$2.0m worth of stock

CEO & Executive Director recently bought HK$2.0m worth of stock

CEO & Executive Director recently bought HK$658k worth of stock

CEO & Executive Director recently bought HK$79k worth of stock

CEO & Executive Director recently bought HK$1.9m worth of stock

CEO & Executive Director recently bought HK$1.9m worth of stock

First half 2022 earnings released: CN¥0.01 loss per share (vs CN¥0.057 profit in 1H 2021)

Fusen Pharmaceutical Company Limited Does Not Recommend Dividend for the Six Months Ended June 30, 2022

Fusen Pharmaceutical Company Limited Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2022

Fusen Pharmaceutical Company Limited to Report First Half, 2022 Results on Aug 29, 2022

CEO & Executive Director recently bought HK$157k worth of stock

CEO & Executive Director recently bought HK$1.9m worth of stock

CEO & Executive Director recently bought HK$1.9m worth of stock

Fusen Pharmaceutical Company Limited Declares Final Dividend for the Year Ended 31 December 2021

Less than half of directors are independent

Investor sentiment improved over the past week

CEO & Executive Director recently bought HK$856k worth of stock

CEO & Executive Director recently bought HK$2.1m worth of stock

Investor sentiment deteriorated over the past week

First half 2021 earnings released: EPS CN¥0.057 (vs CN¥0.044 in 1H 2020)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Here's Why Fusen Pharmaceutical (HKG:1652) Can Manage Its Debt Responsibly

First half 2021 earnings released: EPS CN¥0.057 (vs CN¥0.044 in 1H 2020)

Investor sentiment deteriorated over the past week

Fusen Pharmaceutical Company Limited Approves Final Dividend for the Year Ended 31 December 2020

Investor sentiment deteriorated over the past week

Full year 2020 earnings released: EPS CN¥0.089 (vs CN¥0.067 in FY 2019)

Fusen Pharmaceutical (HKG:1652) Seems To Use Debt Quite Sensibly

Full year 2020 earnings released: EPS CN¥0.09 (vs CN¥0.067 in FY 2019)

Investor sentiment improved over the past week

Fusen Pharmaceutical Company Limited to Report Fiscal Year 2020 Results on Mar 31, 2021

A Look At Fusen Pharmaceutical's (HKG:1652) Share Price Returns

New 90-day low: HK$4.17

We Wouldn't Rely On Fusen Pharmaceutical's (HKG:1652) Statutory Earnings As A Guide

Company Secretary has left the company

Fusen Pharmaceutical Company Limited Announces Executive Changes, with Effect from 29 January 2021

Is Fusen Pharmaceutical Company Limited's (HKG:1652) Recent Price Movement Underpinned By Its Weak Fundamentals?

Does Fusen Pharmaceutical (HKG:1652) Have A Healthy Balance Sheet?

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

What You Need To Know About Fusen Pharmaceutical Company Limited's (HKG:1652) Investor Composition

Market bids up stock over the past week

New 90-day high: HK$6.00

If You Had Bought Fusen Pharmaceutical (HKG:1652) Shares A Year Ago You'd Have Earned 34% Returns

Market bids up stock over the past week

New 90-day high: HK$4.69

Market bids up stock over the past week

First half earnings released